Unlock instant, AI-driven research and patent intelligence for your innovation.

Crystalline form of eliglustat hemitartrate, process for preparation and pharmaceutical composition containing said crystalline form

A kind of hemi-tartrate, the form of technology, used in the field of medicine

Active Publication Date: 2020-04-03
北京启慧生物医药有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The drug is not yet on the market in China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline form of eliglustat hemitartrate, process for preparation and pharmaceutical composition containing said crystalline form
  • Crystalline form of eliglustat hemitartrate, process for preparation and pharmaceutical composition containing said crystalline form
  • Crystalline form of eliglustat hemitartrate, process for preparation and pharmaceutical composition containing said crystalline form

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: Referring to the example of patent CN201510703628.2, to synthesize eliglustat, the specific steps are as follows.

[0040] 1. Preparation of the compound of formula (Ⅲ)

[0041] Add the compound of formula (II) (278g, 1mol) and acetonitrile (2.8L) into a 5L round-bottom three-necked flask equipped with a drying tube, add potassium carbonate (276g, 2mol) under stirring, and add Boc anhydride dropwise in an external bath at 10°C (327g, 1.5mol) in acetonitrile (300mL) solution, continue to react for 3h after addition, then add water (3L), extract three times with ethyl acetate (800mL×3), combine organic phases, wash with saturated brine (800mL) Wash, dry over anhydrous sodium sulfate, filter, and concentrate to obtain 368 g of light yellow oil, with a yield of 97.6%.

[0042]

[0043] 2. Preparation of the compound of formula (Ⅳ)

[0044] In a 5L round-bottom three-neck flask equipped with a drying tube, add the compound of formula (Ⅲ) (302g, 0.8mol) and DM...

Embodiment 2

[0055] Example 2: Preparation of Eliglustat Hemitartrate Crystals

[0056] At room temperature, the eligrusastat (10 g / 24.7 mmol) prepared in Example 1 was dissolved in 140 ml of methanol / acetone (v / v: 0.05:0.95) solution. Take L-tartaric acid (1.84g / 12.3mmol) and add it to 60ml of methanol / acetone (v / v: 0.05:0.95) solution, heat to 40°C, the solid is completely dissolved, and drop this solution into the former solution. After stirring at room temperature for ten minutes, a small amount of solids slowly precipitated out, and after fifteen minutes, a large amount of solids precipitated out. After stirring for another 3 hours, it was filtered, and the filter cake was rinsed with 20ml*2 acetone, and the solids were vacuum-dried at 50°C for 16-20 hours to obtain Off-white solid 9.18g, yield 77.5%.

Embodiment 3

[0057] Example 3: Preparation of Eliglustat Hemitartrate Crystals

[0058] At room temperature, the eligrusastat (10 g / 24.7 mmol) prepared in Example 1 was dissolved in 140 ml of water / acetone (v / v: 0.01:0.99) solution. Take L-tartaric acid (1.84g / 12.3mmol) and add it to 60ml of water / acetone (v / v: 0.01:0.99) solution, heat to 40°C, the solid is completely dissolved, and drop this solution into the former solution. After stirring at room temperature for ten minutes, a large amount of solid precipitated rapidly. After stirring for another 3 hours, it was filtered, rinsed with 2*20ml of acetone, and the solid was vacuum-dried at 60°C for 16-20 hours to obtain 9.78g of off-white solid, with a yield of 82.5%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a crystal form, as shown in a formula I (a) which is described in the specification, of eliglustat hemitartrate and a preparation method thereof, and a pharmaceutical composition containing the crystal form. In an X-ray powder diffraction pattern, the crystal form of eliglustat hemitartrate has main characteristic peaks when a 2theta angle is equal to 10.2 degrees, 12.4 degrees, 13.6 degrees, 14.9 degrees, 20.1 degrees and 22.1 degrees; and according to a DSC pattern, the crystal form has an endothermic peak at a temperature of 161 DEG C to 162 DEG C. The crystal form of eliglustat hemitartrate has the advantage of good stability. The prepared pharmaceutical composition has the advantage of good dissolution, and the crystal is applicable as a bulk drug for production and storage of pharmaceutical preparations.

Description

technical field [0001] The invention relates to a crystalline form of eliglustat hemitartrate, a preparation method, a pharmaceutical composition containing the crystalline form and an application thereof, belonging to the technical field of medicine. Background technique [0002] Eliglustat, the chemical name is N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxan-6-yl)-2-hydroxy- 1-(1-pyrrolidinylmethyl) ethyl] octanamide is the first small molecule compound used to treat specific type I Gaucher disease, and its structural formula is as shown in formula I: [0003] [0004] There are 7,000 types of rare diseases known in the world, accounting for 10% of human diseases. China has discovered 5,781 types of rare diseases, with more than 10 million patients. Gaucher's disease is the most common genetic rare disease of lysosomal storage disease, which is caused by the reduction or deficiency of β-glucocerebrosidase, which makes glucocerebroside in the mononuclear macrophage system A ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D319/18A61K31/4025A61P43/00
CPCC07B2200/13C07D319/18
Inventor 刘素云冯朴纯
Owner 北京启慧生物医药有限公司